

AD \_\_\_\_\_

GRANT NO:


DAMD17-94-J-4386

TITLE:

Detection and Characterization of Autoantigens in Breast Cancer

PRINCIPAL INVESTIGATOR:

Janis Racevskis, Ph.D.



CONTRACTING ORGANIZATION:

Montefiore Medical Center  
Bronx, New York 10467

REPORT DATE:

August 9, 1995

TYPE OF REPORT:

Annual

PREPARED FOR:

U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19950925 138

DTIC QUALITY INSPECTED 5

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

<b>1. AGENCY USE ONLY (Leave blank)</b>		<b>2. REPORT DATE</b> Aug. 9, 1995	<b>3. REPORT TYPE AND DATES COVERED</b> Annual 15 Jul 94 - 14 Jul 95	
<b>4. TITLE AND SUBTITLE</b> Detection and Characterization of Autoantigens in Breast Cancer			<b>5. FUNDING NUMBERS</b> DAMD17-94-J-4386	
<b>6. AUTHOR(S)</b> Dr. Janis Racevskis				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Montefiore Medical Center Bronx, New York 10467			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING/MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b>  Approved for public release distribution unlimited			<b>12b. DISTRIBUTION CODE</b>	
<b>13. ABSTRACT (Maximum 200 words)</b> By screening cDNA libraries from primary ductal breast carcinomas with autologous patient serum, we have detected and isolated three immunoreactive cDNA clones. One of the isolated breast tumor autoantigens ( <i>Ngp-1</i> ), encodes a GTP-binding protein which belongs to a newly described subfamily of GTPases. Immunohistochemical analysis of tissue sections revealed that the antigen was exclusively localized in the nucleolus and nucleolar organizer regions in all cell types analyzed. The second autoantigen isolate ( <i>Auag2</i> ) is also a newly discovered gene product which is not expressed in transformed breast tumor epithelial cell lines, but is however detectable in breast tumors. The sequence of <i>AuAg2</i> bears a partial homology to human heparin-binding angiogenic vascular endothelial growth factor. The third potential isolate remains to be characterized, and more cDNAs are being screened with breast cancer patient serum to identify additional autoantigens.				
<b>14. SUBJECT TERMS</b> Breast Cancer autoantigens GTP-binding protein Nucleolus			<b>15. NUMBER OF PAGES</b> 9	
			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

*Enclosure*

## GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet *optical scanning requirements*.

**Block 1. Agency Use Only (Leave blank).**

**Block 2. Report Date.** Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3. Type of Report and Dates Covered.** State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4. Title and Subtitle.** A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5. Funding Numbers.** To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

<b>C</b> - Contract	<b>PR</b> - Project
<b>G</b> - Grant	<b>TA</b> - Task
<b>PE</b> - Program Element	<b>WU</b> - Work Unit Accession No.

**Block 6. Author(s).** Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7. Performing Organization Name(s) and Address(es).** Self-explanatory.

**Block 8. Performing Organization Report Number.** Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es).** Self-explanatory.

**Block 10. Sponsoring/Monitoring Agency Report Number.** (If known)

**Block 11. Supplementary Notes.** Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a. Distribution/Availability Statement.**

Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

**DOD** - See DoDD 5230.24, "Distribution Statements on Technical Documents."

**DOE** - See authorities.

**NASA** - See Handbook NHB 2200.2.

**NTIS** - Leave blank.

**Block 12b. Distribution Code.**

**DOD** - Leave blank.

**DOE** - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

**NASA** - Leave blank.

**NTIS** - Leave blank.

**Block 13. Abstract.** Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

**Block 14. Subject Terms.** Keywords or phrases identifying major subjects in the report.

**Block 15. Number of Pages.** Enter the total number of pages.

**Block 16. Price Code.** Enter appropriate price code (*NTIS only*).

**Blocks 17. - 19. Security Classifications.** Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

**Block 20. Limitation of Abstract.** This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

JR For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

JR In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

JR In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Janis Racevskis 8/9/95  
PI - Signature Date

TABLE OF CONTENTS

	<u>PAGE</u>
FRONT COVER	1
REPORT DOCUMENTATION PAGE	2
FOREWORD	3
TABLE OF CONTENTS	4
INTRODUCTION	5
BODY	6-7
CONCLUSIONS	8
REFERENCES	8
PUBLICATIONS	9
PERSONNEL RECEIVING PAY	9

Accession For	
NTIS CRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification _____	
By _____	
Distribution / _____	
Availability Codes	
Dist	Avail and/or Special
A-1	

## INTRODUCTION

Tumor growth is associated with the expression of mutated gene products, inappropriate gene expression, and the breakdown of tissue architecture, leading to the exposure and release into the peripheral circulation of sequestered antigens. Whether these circulating, mutated or newly displayed tumor-associated antigens elicit an autologous humoral immune response in the breast tumor patient is of vital interest. Isolation, identification and characterization of novel breast tumor associated autoantigens might yield new insights into the disease process, and moreover, may be developed into diagnostic screening tests and potential targets for immunotherapy.

The screening of cDNA expression libraries with autologous patient serum is a powerful technique, which has been used successfully for the identification of autoimmune disease antigens, and which we have adapted for the identification of autoantigens in cDNA libraries made from breast tumor mRNA. After screening cDNA libraries, derived from primary ductal breast carcinomas with autologous patient serum, we have detected and isolated two immunoreactive cDNA clones. Homology search sequence analysis showed that they could not be matched to any sequences present in the current Genbank database. Encouraged by our initial findings, we proposed to characterize the identified autoantigens and to construct additional cDNA libraries and screen them with autologous serum to identify and isolate additional breast tumor autoantigen cDNAs. The ultimate goals of our research project are: 1. To isolate autoantigen clones which individually or in combination react specifically with most breast tumor patient sera and may form the basis for the development of diagnostic tests or perhaps identify potential targets for immunotherapy, and, 2. To test the hypothesis that breast tumors result in the expression of a characteristic profile of autoantigens.

**BODY**

We have made considerable progress in the characterization of the first of our isolated breast tumor autoantigens, and have submitted our findings for publication (see publications, page 9).

We have named the gene encoding this autoantigen *Ngp-1*, and have determined that it encodes a GTP-binding protein. The revelation that the autoantigen is a GTP binding protein (or GTPase) is especially exciting, since GTPases are highly conserved molecular switches which control proliferation and differentiation of animal cells. GTPases are often targets of mutation and microbial toxins, and have pivotal roles in the pathogenesis of cancer and infectious diseases (1).

The complete 2.3 kb nucleotide sequence of the *Ngp-1* cDNA was found to contain an open reading frame which could encode a protein of 731 amino acids. The predicted amino acid sequence contains a high concentration of charged amino acids in the carboxy terminal quarter of the molecule, three GTP-binding protein motifs and a consensus nuclear localization signal. The arrangement and spacing of the GTP binding protein motifs indicate that *Ngp-1* belongs to a newly described subfamily of GTPases with one other known human member, the others being of prokaryotic origin (2). Except for the consensus motifs, neither nucleotide sequence, nor the predicted amino acid sequence of the *Ngp-1* cDNA showed the slightest homology to any vertebrate gene product sequence listed in the databases. It did however, show high homology to an uncharacterized partial cDNA sequence derived from rice callus. The homology with such a distant organism indicates that this gene must play a very fundamental role in cell growth. Northern blot analysis showed the 2.3 kb transcript to be ubiquitously expressed at relatively low levels in all human tissues tested, with the highest level of expression in the testes. Immunohistochemical analysis of tissue sections with affinity purified antiserum raised against a recombinant *Ngp-1* protein revealed that the antigen was exclusively localized in the nucleolus and nucleolar organizer regions in all cell types analyzed (hence our proposed name *Ngp-1*: Nucleolar G-Protein gene 1).

Since all GTPases interact with other cellular macromolecules, the next phase in our characterization of *Ngp-1* suggests itself: the identification of other gene product/products which interact with *Ngp-1* during its regulatory functions. To accomplish this we have subcloned the entire open reading frame portion of *Ngp-1* into an expression vector, and have begun to purify the full length encoded

protein. This recombinant *Ngp-1* protein will be used in binding studies with nuclear extracts to isolate target binding proteins, which will be identified by two dimensional gel electrophoresis, electrotransferred to membranes, isolated and subjected to micro amino acid sequencing for identification. If partial amino acid sequence analysis does not identify a known gene product, then degenerate oligonucleotide primers based on the amino acid sequences, will be designed for isolation of the corresponding cDNAs, and further characterization.

We have also begun to screen genomic human DNA libraries to isolate the entire *Ngp-1* gene, for eventual sequencing.

Our work on characterization of our second breast tumor autoantigen isolate (working name *Auag2*) is proceeding, and we have isolated cDNA clones encompassing most of the gene product, as judged by the size of the mRNA on Northern blots. One slight complicating factor in determining the sequence of *Auag2* is that in Northern blots, the mRNA appears as a doublet of approximately 1.7 and 1.9 kb. The isolated clones are presently being sequenced, and according to our latest data, this autoantigen is also a newly discovered gene product. Northern blot analysis indicates that *Auag2* is not expressed in transformed breast tumor epithelial cell lines, but is however detectable in breast tumor mRNA. Since breast tumors are a heterogeneous mix of many cell types, *Auag2* might be expressed by infiltrating lymphocytes or stromal fibroblasts. Localization of the autoantigen will have to await production of antiserum against recombinant *Auag2*. The available sequence bears a partial homology to human heparin-binding angiogenic vascular endothelial growth factor, a similarity with great potential relevance to breast cancer.

While work is continuing to characterize the two autoantigen isolates, we are also continuing to collect breast tumor tissue, normal breast tissue, other tumor types, patient serum and constructing more cDNA libraries for screening. Instead of screening a cDNA library with the single autologous patient serum as was done initially, we now screen with a "cocktail" mixture of breast cancer patient sera in order to increase our chances of finding autoantigens. One additional potential autoantigen clone has been isolated and will be characterized.

## CONCLUSIONS

Because of the nature of our research project, we find it most productive to conduct most aspects of the work concurrently (collection of tumors and serum, construction of cDNA libraries, screening of cDNA libraries, isolation of immunoreactive clones, sequencing of clones and characterization). We think we are well on schedule with our statement of work. Because of the open ended nature of our project (we cannot predict how many immunoreactive breast tumor autoantigens we will identify), we might have to limit to what degree of detail to characterize each isolate, depending on our success rate in identifying autoantigens. Every effort will be made to characterize the isolates as fully as possible, since for newly discovered gene products, understanding their function will be a very important contribution to the understanding of breast tumor biology.

## REFERENCES

Bourne, H.R., Sanders, D.A., and McCormick, F. The GTPase superfamily: conserved structure and molecular mechanism. *Nature*, 349:117-127, 1991.

Vernet, C., Ribouchon, M.-T., Chimini, G., and Pontarotti, P. Structure and evolution of a member of a new subfamily of GTP-binding proteins mapping to the human MHC class I region. *Mammalian Genome*, 5:100-105, 1994.

RACEVSKIS, Janis

**PUBLICATIONS**

**Cloning of a novel nucleolar GTP-binding protein from a breast tumor. Janis Racevskis, Alyssa Dill, Richard Stockert and Susan A. Fineberg. Submitted.**